HEPAVEC AG FUER GENTHERAPIE has a total of 17 patent applications. Its first patent ever was published in 1997. It filed its patents most often in Germany, WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets biotechnology and pharmaceuticals are SYNTRO CORP, CHENGDU INST OF BIOLOGICAL PRODUCTS CO LTD and ASKLEPIOS BIOPHARMACEUTICAL INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Germany | 8 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Canada | 3 | |
#4 | EPO (European Patent Office) | 1 | |
#5 | United States | 1 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Peptides | |
#3 | Medical preparations | |
#4 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Strauss Michael | 9 |
#2 | Hofmann Christian | 8 |
#3 | Loeser Peter | 5 |
#4 | Kirillowa Ira | 4 |
#5 | Hillgenberg Moritz | 3 |
#6 | Strauss Michael Prof Dr | 2 |
#7 | Sandig Volker | 2 |
#8 | Lukas Jiri | 1 |
#9 | Schnieders Frank | 1 |
#10 | Bartek Jiri | 1 |
Publication | Filing date | Title |
---|---|---|
DE10019006A1 | Novel adenoviral vector for gene transfer, its application and its production | |
DE10006886A1 | Non-human helper dependent virus vector | |
DE10001390A1 | Cell line for the production and production of sheep adenovirus vectors | |
WO9902647A2 | Cloning vectors for producing adenoviral minimal viruses | |
CA2283090A1 | Method for induction of apoptotic cell death in malignant cells, through reduction of the rb to apoptosis inducing proteins ratio | |
DE19754103A1 | New packaging cell line for E1-deleted adenovirus | |
DE19735593A1 | Coat protein-modified baculovirus vector for gene therapy | |
DE19711266A1 | New human liver cell line |